PCN139 BUDGET IMPACT ANALYSIS OF NILOTINIB AS FIRST LINE TREATMENT OF NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) WITH HIGH RISK SOKAL SCORE IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.335
https://www.valueinhealthjournal.com/article/S1098-3015(19)32713-5/fulltext
Title :
PCN139 BUDGET IMPACT ANALYSIS OF NILOTINIB AS FIRST LINE TREATMENT OF NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) WITH HIGH RISK SOKAL SCORE IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)32713-5&doi=10.1016/j.jval.2019.09.335
First page :
Section Title :
Open access? :
No
Section Order :
10273